- /
- Supported exchanges
- / US
- / ORINY.PINK
Orion Oyj ADR (ORINY PINK) stock market data APIs
Orion Oyj ADR Financial Data Overview
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Orion Oyj ADR data using free add-ons & libraries
Get Orion Oyj ADR Fundamental Data
Orion Oyj ADR Fundamental data includes:
- Net Revenue: 2 177 M
- EBITDA: 884 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-09-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Orion Oyj ADR News
New
Orion Oyj (HLSE:ORNBV) Stock Richly Valued Despite Q3 Earnings Surge
Orion Oyj stock closed at €95.95 on 28 October, capping a strong run over the past quarter, just as Q3 2026 numbers landed. The headline is simple. Earnings kept tracking higher while the valuation ...
Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline
Orion Oyj ORION CORPORATION INTERIM REPORT 1–9/2026 28 OCTOBER 2026 at 12:00 EET Orion Group Interim report January–September 2026: Strong financial performance and positive developments in ...
Is Orion Oyj (HLSE:ORNBV) Fully Priced On Phase 3 Darolutamide Trial News?
Interim Phase 3 data around darolutamide has put Orion Oyj (HLSE:ORNBV) back in focus, with investors weighing fresh oncology trial results, upgraded 2026 guidance and an upcoming reshuffle of the exe...
Changes in Orion Group’s Executive Team as of 1 January 2027
Orion Oyj Photo: Henri SalokangasPhoto: Henri Salokangas ORION CORPORATION STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS 26 October 2026 at 13.00 EET Changes in Orion Group's Exe...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.